TNFRSF10B and triple-negative breast carcinoma: Nanocarriers also facilitate the delivery of receptor agonist antibodies, such as DR5 antibodies conjugated with solid lipid nanoparticles for the selective targeting of cancer cells in triple-negative breast cancer (TNBC) therapy [124].